Management of hepatitis C among drug user patients;Prise en charge de l'hépatite C chez les patients utilisateurs de drogues

Gastroenterologie Clinique et Biologique

Volumn 31, Issue 8-9 C3, 2007, Pages

  Moussalli, Joseph ^a   Melin, Pascal ^b   Wartelle Bladou, Claire ^c   Lang, Jean Philippe ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre Hospitalier Général   (France)

^c CENTRE HOSPITALIER DU PAYS D AIX   (France)

^d Centre Hospitalier d Erstein   (France)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE;

ADULT; AGED; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG ABUSE; DRUG USE; HEALTH CARE ACCESS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MENTAL DISEASE; PATIENT COMPLIANCE; REINFECTION; TREATMENT RESPONSE;

EID: 35848968501     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0399-8320(07)92564-6     Document Type: Article

References (42)

1. Roudot-Thoraval F. Modifications of epidemiological characteristics of hepatitis C. Gastroenterol Clin Biol 2002 Apr;26 Spec No 2:B138-43.
2. Diamantis I, Basseti, Erb P, Ladewig D, Gyr K, Battegay M. High prevalence and co infection rate of hepatitis G and C infections in intravenous drug addicts. J Hepatol 1997;26:794-7.
3. Alter MJ. Epidemiology oh hepatitis C. Hepatology 1997;26:62S-65 S.
4. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States 1988 through 1994. N Engl J Med 1999;341:556-62.
5. Guyader D, Lefeuvre C, Jacquelinet S, Prat M, Baudouerd Y, Turlin B, et al. Epidémiologie de l'infection virale C chez 1 304 sujets VHC positifs. Variations en fonction du mode de contamination et de l'année du diagnostic. Gastroenterol Clin Biol 1998;22(4):375-80.
6. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999;107 (6B):2S-9S.
7. Poynard T, Bedossa P, Opolon, P, The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997 Mar 22;349(9055):825-32.
8. Pol S, Lamorthe B, Trin Thi N, Thiers V, Carnot F, Zylberberg H, et al. Retrospective analysis oh the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 1998;28:945-50.
9. Roudot-Thoraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease:a French survey of 6,664 patients. Hepatology 1997;26:485-90.
10. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. the natural history of hepatitis C virus infection. Host, viral and environmental factors. JAMA 2000;284:450-6.
11. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend 2001;61:211-5.
12. Cacoub P, Giderel I, Morlat P, Sene D, Myers RP, Alric L, et al. Management of chronic hepatitis C in French departments of internal medicine and infectious diseases. Epidemiol Infect 2005 Apr;133(2):305-14.
13. Jowett SL, Agarwal K, Smith BC, Craig W, Hewett M, Bassendine DR, et al. Managing chronic hepatitis C acquired through intravenous drug use. QJM 2001;94(3):153-8.
14. Franken H, Hendriks VM. Predicting outcome of inpatient detoxification of substance abusers. Psychiatr Serv 1999;50:813-7.
15. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva:follow up at 1 ant 6 months. Drug Alcohol Depend 2000;58:85-92.
16. Albanese AP, Gervitz C, Oppenheim B, Field JM, Abels I, Eustace JC. Outcome and six months follow up of patients after ultra rapid opiate detoxification. J Addict Dis 2000;19:11-28.
17. National Institutes of Health Consensus Development Conference panel Statement: Management of hepatitis C. Hepatology 1997;26:71S-7S.
18. EASL. International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999;30:956-61.
19. Management of Hepatitis C. Consensus Statements. NIH development Program. 2002, Vol. 19, no 1.
20. Filoche B. Conférence de Consensus. Traitement de l'hépatite C et usage de drogue. Gastroenterol Clin Biol 2002;26:B252-6.
21. Broers B, Morabia A, Hirschel B. A cohort study of drug users' compliance with Zidovudine treatment. Arch Intern Med 1994;154:1121-7.
22. Moatti JP, Carrieri MP, Spire B, Gastaud JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. AIDS 2000;14:151-1.
23. Gourevitch MN, Wasserman W, Panero MS, Selwyn PA. Succesful adherence to observed prophylaxis and treatment of tuberculosis among drug users in a methadone program. J Addict Dis 1999;15:93-104.
24. Bangsberg DR, Moss A. When should we delay highly active antiretroviral therapy? J Gen Intern Med 1999;14:446-8.
25. Lerner BH, Gulick RM, Dubler NN. Rethinking non adherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med 1998;129:573-8.
26. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in drug users. Hepatology 2001;34:188-93.
27. Moussalli J, Delaquaize H, Boubilley D, Lhomme JP, Merlot Ponty J, Sabot D, et al. Factors improving management of hepatitis C in drug users. An experience in a drug addict's centre (résumé). J Hepatol 2007;46:S211.
28. Edlin B, Kresina T, Raymond D, Carden M, Gourevitch M, Rich J, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005;40 Suppl 5:S276-85.
29. Golub ET, Latka M, Hagan H, Havens JR, Hudson SM, Kapadia F, et al. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004;81(2):278-90.
30. Mason BJ, Kocsis JH, Melia D, Khury ET, Sweeney J, Wells A, et al. Psychiatric comorbidity in methadone maintained patients. J Addict Dis 1998;17(3):75-89.
31. Edel Y. Que dire, que faire en cas de toxicomanie accompagnée d'hépatite virale C. HeaptoGatsro 1999;6:32-5.
32. King VL, Brooner RK. Assessment and treatment of comorboid psychiatric disorders. In: Strains EC, Stitzer ML, eds. Methadone treatment for opiod dependnace. Baltimore: John Hopkins University press, 1999:141-65.
33. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howrd AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377-81.
34. Janssen HL, Brouwer JT, Van Der Mast RC, Schalm SW. Suicide associated with alpha interferon therapy for chronic hepatitis C. J Hepatol 1994;21:241-3.
35. Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, et al. Co-occurring Hepatitis C, substance use, and psychiatric illness:treatment issues and developing integrated models of care. J Urban Health 2004 Dec;81(4):719-34.
36. Sylvestre DL. Approaching treatment for hepatitis C virus infection in substance users. Clin Infect Dis 2005;41:S79-82.
37. Dalgard O, Bjoro K, Hellum K, Myrvang B, Skaug K, Gutigard B, et al. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up. Eur Addict Res 2002;8(1):45-9.
38. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002;67(2):117-23.
39. Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment:a randomized controlled trial. JAMA 2001;286:1715-23.
40. Gourevitch MN, Hartel D, Selwyn PA, Scoeunbeum EE, Klein RS. Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. AIDS 1999;13:2069-74.
41. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002;16:767-74.
42. Cournot M, Glibert A, Castel F, Druart F, Imani K, Lauwers-Cances V, et al. Management of hepatitis C in active drug users:experience of an addiction care hepatology unit. Gastroenterol Clin Biol 2004;28:533-9.